Skip to main content

INVESTIGACIÓN TRASLACIONAL SOBRE SEÑALES ENDOCRINAS Y SU PARTICIPACIÓN EN LA REGULACIÓN DE DIVERSOS PROCESOS PATOFISIOLÓGICOS.

JCI-2009-05675

•
Funding agency name Ministerio de Ciencia e Innovación
Funding agency acronym MICINN
Program Programa Nacional de Contratación e Incorporación de RRHH
Subprogram Subprograma Juan de la Cierva (JDC)
Call Juan de la Cierva Incorporación
Call year 2009
State Plan 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Management unit Subdirección General de Formación e Incorporación de Investigadores
Beneficiary centre UNIVERSIDAD DE CORDOBA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Helvia. Repositorio Institucional de la Universidad de Córdoba
Publication Artículo científico (JournalArticle)

A cellular and molecular basis for the selective desmopressin-induced ACTH release in Cushing disease patients: key role of AVPR1b receptor and potential therapeutic implications

  • Luque, Raúl M.
  • Ibáñez-Costa, Alejandro
  • López-Sánchez, Laura María
  • Jiménez Reina, L.
  • Venegas-Moreno, Eva
  • Gálvez-Moreno, M. Ángeles
  • Villa-Osaba, Alicia
  • Madrazo Atutxa, Ainara M.
  • Japón, Miguel Ángel
  • de la Riva, Andrés
  • Cano, David A.
  • Benito-López, Pedro
  • Soto-Moreno, Alfonso
  • Gahete Ortiz, Manuel D.
  • Leal-Cerro, Alfonso
  • Castaño, Justo P.
Context: Desmopressin is a synthetic agonist of vasopressin receptors (AVPRs). The desmopressin stimulation test is used in the diagnosis and postsurgery prognosis of Cushing disease (CD). However, the cellular and molecular mechanisms underlying the desmopressin-induced ACTH increase in patients with CD are poorly understood. Objective: The objectives of this study were to determine, for the first time, whether desmopressin acts directly and exclusively on pituitary corticotropinoma cells to stimulate ACTH expression/release and to elucidate the cellular and molecular mechanisms involved in desmopressin-induced ACTH increase in CD. Design: A total of 8 normal pituitaries (NPs), 23 corticotropinomas, 14 nonfunctioning pituitary adenomas, 17 somatotropinomas, and 3 prolactinomas were analyzed for AVPR expression by quantitative real-time RT-PCR. Primary cultures derived from corticotropinomas, nonfunctioning pituitary adenomas, somatotropinomas, prolactinomas, and NPs were treated with desmopressin, and ACTH secretion/expression, [Ca2+]i kinetics, and AVPR expression and/or proliferative response were evaluated. The relationship between AVPR expression and plasma adrenocorticotropin/cor-tisol levels obtained from desmopressin tests was assessed. Results: Desmopressin affects all functional parameters evaluated in corticotropinoma cells but not in NPs or other pituitary adenomas cells. These effects might be due to the dramatic elevation of AVPR1b expression levels found in corticotropinomas. In line with this notion, the use of an AVPR1b antagonist completely blocked desmopressin stimulatory effects. Remarkably, only AVPR1b expression was positively correlated with elevated plasma adrenocorticotropin levels in corticotropinomas. Conclusions: The present results provide a cellular and molecular basis to support the desmopressin stimulation test as a reliable, specific test for the diagnosis and postsurgery prognosis of CD. Furthermore, our data indicate that AVPR1b is responsible for the direct/exclusive desmopressin stimulatory pituitary effects observed in CD, thus opening the possibility of exploring AVPR1b antagonists as potential therapeutic tools for CD treatment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Truncated Isoform of Somatostatin Receptor5 (sst5TMD4) Is Associated with Poorly Differentiated Thyroid Cancer

  • Puig Domingo, Manuel|||0000-0002-6744-7195
  • Luque, Raúl M.|||0000-0002-7585-1913
  • Reverter Calatayud, Jorge Luis|||0000-0003-0362-2035
  • López-Sánchez, Laura M.
  • Gahete, Manuel D.
  • Culler, Michael D.
  • Díaz-Soto, Gonzalo|||0000-0001-9743-9412
  • Lomeña, Francisco
  • Squarcia, Mattia
  • Mate Sanz, Jose Luís|||0000-0002-4829-3426
  • Mora, Mireia|||0000-0002-5887-5016
  • Fernández-Cruz, Laureano
  • Vidal, Oscar
  • Alastrue Vidal, Antonio|||0000-0002-8395-8438
  • Balibrea Del Castillo, José María|||0000-0002-0764-7179
  • Halperin, Irene|||0000-0003-3151-5990
  • Mauricio, Didac|||0000-0002-2868-0250
  • Castaño, Justo P.|||0000-0002-3145-7287
Somatostatin receptors (ssts) are expressed in thyroid cancer cells, but their biological significance is not well understood. The aim of this study was to assess ssts in well differentiated (WDTC) and poorly differentiated thyroid cancer (PDTC) by means of imaging and molecular tools and its relationship with the efficacy of somatostatin analog treatment. Thirty-nine cases of thyroid carcinoma were evaluated (20 PDTC and 19 WDTC). Depreotide scintigraphy and mRNA levels of sst-subtypes, including the truncated variant sst5TMD4, were carried out. Depreotide scans were positive in the recurrent tumor in the neck in 6 of 11 (54%) PDTC, and in those with lung metastases in 5/11 cases (45.4%); sst5TMD4 was present in 18/20 (90%) of PDTC, being the most densely expressed sst-subtype, with a 20-fold increase in relation to sst2. In WDTC, sst2 was the most represented, while sst5TMD4 was not found; sst2 was significantly increased in PDTC in comparison to WDTC. Five depreotide positive PDTC received octreotide for 3-6 months in a pilot study with no changes in the size of the lesions in 3 of them, and a significant increase in the pulmonary and cervical lesions in the other 2. All PDTC patients treated with octreotide showed high expression of sst5TMD4. ROC curve analysis demonstrated that only sst5TMD4 discriminates between PDTC and WDTC. We conclude that sst5TMD4 is overexpressed in PDTC and may be involved in the lack of response to somatostatin analogue treatment.